دورية أكاديمية
Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
| العنوان: | Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes |
|---|---|
| المؤلفون: | Junko Oya, Tomoko Nakagami, Yukiko Hasegawa, Aki Katamine, Yuichiro Kondo, Tetsuya Babazono |
| المصدر: | Journal of Diabetes Investigation, Vol 12, Iss 11, Pp 1983-1991 (2021) |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Diseases of the endocrine glands. Clinical endocrinology |
| مصطلحات موضوعية: | Insulin degludec, Insulin glargine 300 U/mL, Real‐world clinical setting, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| الوصف: | Abstract Aims/Introduction To evaluate and compare the efficacy of insulin degludec (IDeg) and insulin glargine 300 U/mL (Gla300) 6 months after switching from other basal insulins by assessing the changes in glycated hemoglobin (HbA1c), body mass index (BMI), and insulin doses in patients with type 1 and type 2 diabetes in a real‐world clinical setting. Materials and Methods A total of 307 patients with type 1 diabetes and 294 patients with type 2 diabetes with HbA1c >7.0% were studied. Adjusted mean changes in HbA1c, BMI, and insulin doses were compared between IDeg (IDeg group) and Gla300 (Gla300 group) switchers. Multivariable logistic regression analyses were carried out to examine whether the IDeg or Gla300 group was associated with HbA1c or insulin dose reduction and BMI gain. Results HbA1c was significantly decreased in both the IDeg and Gla300 groups. Adjusted mean changes in HbA1c (approximately −0.3% and −0.5% in type 1 diabetes and type 2 diabetes patients, respectively) and BMI were similar between both groups. The mean change in insulin dose was slightly larger for dose reduction in the IDeg group than in the Gla300 group. Multivariable logistic regression models showed that the IDeg group was significantly associated with insulin dose reduction after adjusting for basal insulin type, insulin dose, and number of basal insulin injections at baseline and other confounding factors. Conclusions The current study suggested that IDeg and Gla300 have similar effects in reducing HbA1c and gaining BMI after switching from other basal insulins in Japanese patients with type 1 diabetes and type 2 diabetes. IDeg selection was associated with insulin dose reduction. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2040-1124 2040-1116 |
| العلاقة: | https://doaj.org/toc/2040-1116Test; https://doaj.org/toc/2040-1124Test |
| DOI: | 10.1111/jdi.13559 |
| الوصول الحر: | https://doaj.org/article/33e2f17798204034beea375b21f2d506Test |
| رقم الانضمام: | edsdoj.33e2f17798204034beea375b21f2d506 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20401124 20401116 |
|---|---|
| DOI: | 10.1111/jdi.13559 |